The current investment thesis for Gentex is multifaceted, sending conflicting signals to the market. While institutional investors have made significant portfolio adjustments and the company has raised its full-year guidance following an acquisition, a closer look at its latest quarterly report reveals underlying challenges in its core business.
Quarterly Performance and Revised Forecast
For the third quarter of 2025, Gentex reported earnings per share (EPS) of $0.46, narrowly missing the analyst consensus estimate of $0.47. Consolidated net sales, which now include contributions from the acquired VOXX Electronics, rose 8% year-over-year to $655.2 million. VOXX contributed $84.9 million of this total. However, the company’s core revenue, excluding VOXX, declined by 6% to $570.3 million compared to Q3 2024.
A breakdown of the automotive segment shows revenues decreased from $596.5 million to $558.0 million. This drop was attributed primarily to lower shipments of auto-dimming mirrors to Europe and China, partially offset by growth in advanced-feature mirrors in North America.
Key Q3 2025 Financial Metrics:
* Consolidated Net Sales: $655.2 million (+8% Y/Y)
* Core Revenue (ex-VOXX): $570.3 million (-6% Y/Y)
* Earnings Per Share: $0.46 (Consensus: $0.47)
* Consolidated Operating Income: $122.3 million (Prior: $125.7 million)
Integrating VOXX has led management to raise the full-year outlook. Consolidated revenue is now projected to be between $2.5 billion and $2.6 billion, compared to a prior range of $2.44 billion to $2.61 billion. Expectations for the core business stand at $2.14-$2.15 billion, with China forecast at $135-$145 million (up from $100-$125 million). VOXX is expected to contribute $250-$275 million. The estimated stand-alone gross margin increased to a range of 34.25% to 34.75%. Analysts project full-year EPS to reach $2.04.
Shifting Institutional Holdings
Recent regulatory filings reveal notable activity among major investors. Several asset managers substantially increased their stakes. Squarepoint Ops boosted its holding by 567.9% in Q2 to 275,091 shares (valued at approximately $6.05 million). Similarly, Fuller & Thaler expanded its position by 487.7% in Q1 to 3,447,651 shares (around $80.33 million). UBS Asset Management grew its stake by 142.3% to 4,589,585 shares (roughly $106.94 million) in the same period.
Should investors sell immediately? Or is it worth buying Gentex?
Conversely, EdgePoint Investment Group reduced its exposure, selling 1,583,578 shares in Q2 for a 21.9% decrease. It continues to hold a significant position of 5,637,882 shares, worth approximately $123.98 million.
Valuation, Dividend, and Market Sentiment
Gentex declared a quarterly cash dividend of $0.12 per share, offering a dividend yield of 2.02%. The ex-dividend date is set for January 7, 2026. The company’s payout ratio was 28.24%, with next year’s estimate at 22.33%.
Trading recently around $23.67 after a slight decline on December 13, the equity has a 52-week range of $20.28 to $30.65. With a market capitalization of $5.18 billion, the stock trades at a price-to-earnings (P/E) ratio of approximately 13.92, which sits below both the broader market and sector averages.
Analyst opinions are mixed. MarketBeat reports a consensus price target of $28.29, implying a potential upside of about 19.5%. MarketScreener notes that the consensus view has deteriorated recently, with individual estimates showing significant variance.
The Bottom Line
The raised annual guidance provides a supportive narrative for the consolidated entity, but this is partly reliant on contributions from VOXX and improved performance in China. The core business remains under pressure, and if these declines persist, they could weigh on future profitability. The upcoming ex-dividend date and next quarterly earnings report will serve as key milestones for investors to assess whether the new revenue streams can successfully offset the weakness in the legacy operations.
Ad
Gentex Stock: Buy or Sell?! New Gentex Analysis from December 16 delivers the answer:
The latest Gentex figures speak for themselves: Urgent action needed for Gentex investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from December 16.
Gentex: Buy or sell? Read more here...
